Thermo Fisher Scientific Inc. (NYSE:TMO) Plans Quarterly Dividend of $0.43

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) declared a quarterly dividend on Thursday, July 10th, RTT News reports. Shareholders of record on Monday, September 15th will be paid a dividend of 0.43 per share by the medical research company on Wednesday, October 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. The ex-dividend date is Monday, September 15th.

Thermo Fisher Scientific has a dividend payout ratio of 7.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Thermo Fisher Scientific to earn $25.56 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 6.7%.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $4.29 during trading on Friday, reaching $435.02. The company's stock had a trading volume of 2,511,384 shares, compared to its average volume of 1,999,630. The stock has a market capitalization of $164.22 billion, a PE ratio of 25.51, a P/E/G ratio of 2.31 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The firm has a fifty day moving average of $409.39 and a 200 day moving average of $476.23. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company's revenue was up .2% on a year-over-year basis. During the same period in the prior year, the company earned $5.11 EPS. Analysts expect that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

An institutional investor recently raised its position in Thermo Fisher Scientific stock. Brighton Jones LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 28.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,409 shares of the medical research company's stock after buying an additional 988 shares during the quarter. Brighton Jones LLC's holdings in Thermo Fisher Scientific were worth $2,293,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on TMO shares. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Argus dropped their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Finally, Robert W. Baird dropped their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $600.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.